Arena Pharmaceuticals Buy Hold or Sell Recommendation

ARNA -- USA Stock  

USD 62.07  0.59  0.96%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Arena Pharmaceuticals is 'Strong Hold'. Macroaxis provides Arena Pharmaceuticals buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ARNA positions. The advice algorithm takes into account all of Arena Pharmaceuticals available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ARNA buy-and-hold prospective. Check also Arena Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for muliple equity instruments please use Instant Ratings tool.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Arena PharmaceuticalsBuy Arena Pharmaceuticals
Strong Hold

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Arena Pharmaceuticals has a risk adjusted performance of 0.1078, jensen alpha of 0.1349, total risk alpha of (0.15), sortino ratio of 0.0751 and treynor ratio of 0.2793
Macroaxis provides unbiased buy, hold, or sell recommendation on Arena Pharmaceuticals that should be used to complement current analysts and expert consensus on Arena Pharmaceuticals. Our buy or sell advice engine determines the organization potential to grow exclusively from the prospective of investors current risk tolerance and investing horizon. To make sure Arena Pharmaceuticals is not overpriced, please confirm all Arena Pharmaceuticals fundamentals including its Current Valuation, Price to Book, Cash and Equivalents, as well as the relationship between Shares Owned by Institutions and Gross Profit . Given that Arena Pharmaceuticals has Number of Shares Shorted of 3.28M, we suggest you validate Arena Pharmaceuticals market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.

Arena Pharmaceuticals Trading Alerts and Improvement Suggestions

Over 85.0% of the company shares are held by institutions such as insurance companies

Arena Pharmaceuticals current analysts recommendations

Target Median Price66.50
Target Mean Price67.10
Recommendation Mean1.80
Target High Price79.00
Number Of Analyst Opinions10
Target Low Price50.00

Arena Pharmaceuticals Returns Distribution Density

Mean Return0.30Value At Risk3.06
Potential Upside3.45Standard Deviation1.94
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Winton Group LtdCommon Shares15.8 K928 K
Xact Kapitalforvaltning AbCommon Shares8.9 K524 K
Exane DerivativesCommon Shares5.4 K315.2 K
Legacy Bridge LlcCommon Shares1.5 K88 K
First Command BankCommon Shares50029 K
Nisa Investment Advisors LlcCommon Shares34020 K
Wellington Management Group LlpCommon Shares5 M222.2 M

Arena Pharmaceuticals Greeks

α
Alpha over DOW
=0.13
β
Beta against DOW=1.04
σ
Overall volatility
=1.97
Ir
Information ratio =0.07

Arena Pharmaceuticals Volatility Alert

Arena Pharmaceuticals has relatively low volatility with skewness of 0.16 and kurtosis of -0.22. However, we advise all investors to independently investigate Arena Pharmaceuticals to ensure market all accessible information is consistent with the expectations about its upside potential and future risk-adjusted return.
    
 Better Than Average     
    
 Worse Than Average Compare Arena Pharmaceuticals to competition

Arena Pharmaceuticals Fundamental Vs Peers

FundamentalsArena PharmaceuticalsPeer Average
Return On Equity68.14% (0.31)%
Return On Asset38.78% (0.14)%
Profit Margin76.19% (1.27)%
Operating Margin76.94% (5.51)%
Current Valuation1.97B16.62B
Shares Outstanding49.57M571.82M
Shares Owned by Insiders0.16% 10.09%
Shares Owned by Institutions85.23% 39.21%
Number of Shares Shorted3.28M4.71M
Price to Earning4.86X28.72X
Price to Book2.42X9.51X
Price to Sales3.70X11.42X
Revenue817.27M9.43B
Gross Profit(97.06M)27.38B
EBITDA628.84M3.9B
Net Income622.7M570.98M
Cash and Equivalents1.1B2.7B
Cash per Share22.28X5.01X
Total Debt58.15M5.32B
Debt to Equity4.60% 48.70%
Current Ratio35.51X2.16X
Book Value Per Share25.09X1.93K
Cash Flow from Operations406.34M971.22M
Short Ratio6.03X4.00X
Earnings Per Share12.49X3.12X
Price to Earnings To Growth(0.35)X4.89X
Number of Employees19418.84K
Beta1.02-0.15
Market Capitalization3.03B19.03B
Total Asset256.79M29.47B
Retained Earnings(312.53M)9.33B
Working Capital124.94M1.48B
Current Asset174.84M9.34B
   Exercise or conversion by Jennifer Bielasz of 6250 shares of Arena Pharmaceuticals subject to Rule 16b-3 [view details]
Search macroaxis.com